AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06204029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyone can sing
Description: The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means.
Study NCT06362408 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Older patients who have used dexmedetomidine(safe use range: 0.2\~1.0 μg/(kg·h)) for anesthesia induction or maintenance during surgery were classified as the DEX group. On the contrary, patients who did not use dexmedetomidine throughout the entire anesthesia process were identified as the Non-DEX group.
Study NCT05421858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmanogepix
Description: IV infusion
Study NCT05421858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmanogepix
Description: Oral tablet
Study NCT05421858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: IV infusion
Study NCT05421858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole oral capsule
Study NCT05421858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for caspofungin (IV infusion)
Study NCT05421858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for fluconazole (oral capsule)
Study NCT05421858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo for fosmanogepix (IV infusion)
Study NCT05421858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo for fosmanogepix (oral tablet)
Study NCT05471843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally
Study NCT06452836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green color exposure
Description: Patients will wear green colored glasses before and during the surgery.
Study NCT06452836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red color exposure
Description: Patients will wear red colored glasses before and during the surgery.
Study NCT06452836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue color exposure
Description: Patients will wear blue colored glasses before and during the surgery.
Study NCT06452836 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Patients will wear translucent glasses before and during the surgery.
Study NCT06572384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered.
Study NCT06572384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT06209684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium
Description: Spinal stabilization using titanium screws and rods
Study NCT06209684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbofix
Description: Spinal stabilization using CarboFix screws and rods
Study NCT06350630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Tablet
Description: Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years
Study NCT06350630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
Study NCT05170204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive oral alectinib twice daily with food.
Study NCT05170204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Participants will receive oral entrectinib once daily, with or without food.
Study NCT05170204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Participants will receive IV durvalumab every 4 weeks.
Study NCT05878769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive SC astegolimab Q2W
Study NCT04715893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ostomy belt
Description: Stealth ostomy belt continuous for eight weeks
Study NCT05835986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7507062
Description: RO7507062 solution for injection will be administered SC as specified in each treatment arm.
Study NCT05835986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants >/= 30 kg or at 12 mg/kg for participants \< 30 kg.
Study NCT05180552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEALiX is an alternative restraint patient safety device
Description: The HEALiX is a rigid, spiral, exoskeleton-like device made of lightweight stainless steel (Austenitic SAE 316 or equivalent) that comes in various sizes to fit different arm lengths circumference of the patient's bicep. After appropriate measuring and following the fit guide, the HEALiX is placed on the patient's arm so that the hand rests on a soft, padded hand cradle. The trajectory of the end hand cradle is at a 30-degree upward angle to prevent peripheral dependent edema. This hand cradle is surrounded by foam to provide increased support for the patient and also to protect the medical team from any injury. A wrist bracelet (wrist assist) goes around the patient's wrist and prevents the patient from removing the device. The spiral exoskeleton holds the arm in a neutral position with contact points with the patient's skin at the upper deltoid region only.
Study NCT05180552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft wrist restraints
Description: Soft wrist restraints are padded cloth restraints that are worn by patients on wrist and secured to bed frame.
Study NCT02809196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1: Tailored SMS program implicating friend and mother
Study NCT02809196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2: Standardized SMS program implicating friend and mother
Study NCT02809196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 3: Tailored SMS program implicating friend, not mother
Study NCT02809196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4: Standardized SMS program implicating friend, not mother
Study NCT02809196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5: Tailored SMS program implicating mother, not friend
Study NCT02809196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6: Standardized SMS program implicating mother, not friend
Study NCT02809196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 7: Tailored SMS program not implicating mother or friend
Study NCT02809196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 8: Standardized SMS program not implicating mother or friend
Study NCT02809196 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 9: No SMS program
Study NCT05467163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacemaker implantation
Description: Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.
Study NCT05467163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing device implantation
Description: Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.
Study NCT05467163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AV node ablation
Description: Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
Study NCT05467163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AV node ablation
Description: Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
Study NCT04646603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001
Description: Subjects will receive subcutaneous MRG-001 injections.
Study NCT04646603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive subcutaneous placebo injections.
Study NCT05336227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exergaming
Description: The VR intervention will include home-based exercise using the Oculus Quest, a heart rate monitor (Polar OH1), BP cuff, and mobile application. The games will include rhythmic movements to music and sport/recreation activities that elicit high energy expenditure. Participants will be instructed to reach 150 minutes per week of moderate-exercise in week 1 and maintain this volume across the 12-week intervention. The intervention will include behavioral, physical education coaching through videoconference, which we refer to as Tele-PE. Tele-PE will aim to enhance adherence, provide basic exercise knowledge, and increase mastery playing the games. Calls will last 15 minutes, and be provided weekly in month 1, bi-weekly in month 2, and one call at the end of month 3.
Study NCT04296630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social media message #1
Description: Social media message promoting colorectal cancer screening
Study NCT04296630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social media message #2
Description: A different social media message promoting colorectal cancer screening
Study NCT04296630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social media message #3
Description: A different social media message promoting colorectal cancer screening
Study NCT04296630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social Media Message #4
Description: A different social media message promoting colorectal cancer screening.
Study NCT04296630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Social Media Message
Description: Tailored social media messages promoting colorectal cancer screening.
Study NCT05724524 — intervention group
Intervention type: OTHER
Intervention: Stool sample collection
Description: 50mg stool sample taken for protein extraction
Study NCT05724524 — intervention group
Intervention type: OTHER
Intervention: Blood sample collection
Description: Venous blood sample taken for analysis of serum and plasma
Study NCT04855487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-patient dyadic storytelling intervention
Description: During the 5-week online intervention, adolescents/young adults with cancer will create their stories following the guiding questions and online meetings with nursing research staff. The target audience of their stories will be their primary nurses. This online dyadic storytelling intervention is designed to promote in-depth self-reflection and meaningful and therapeutic relationships within bedside nurses. The intervention is designed following the Story Theory and Pennebaker's Expressive Writing paradigm.
Study NCT05698654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD)
Description: The subjects will be instructed to follow their usual diet plan, except for 5 days when they eat the foods in the FMD box.The fasting-mimicking diet consists of a blend of 100% plant based nutrients generally regarded as safe. The formulation of these products is based on studies carried out at the Longevity Institute of the University of Southern California and his collaborators over several decades of studies.~This food plan provides for the replacement of the normal diet with the organic plant products contained in the fasting-mimicking diet for five consecutive days.
Study NCT05698654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Longevity Diet (LD) + Fasting-mimicking Diet (FMD)
Description: The subjects will be instructed to follow their longevity diet plan, except for 5 days when they eat the foods in the FMD box, based on the following guidelines:~vegan based diet with the addition of low mercuryfish 2-3 times a week; protein content should be 0.7-0.8 grams per kilogram of ideal weight per day (most of the protein coming from whole cereals,vegetables, legumes and tree nuts only part from fish); monounsaturated and polyunsaturated fats are predominant and very low amounts of saturated and trans-fats are allowed; complex Carbohydrates from vegetables, whole grains and legumes; addition of vitamins, minerals and Omega3 fats; food selected between the traditional food consumed by ancestry; time-restricted feeding: all food must be consumed within 12 hours each day. for those who are overweight or are nearly overweight (BMI >25 kg/m2), either lunch or dinner will be substituted with a low calorie, low sugar snack (approximately 100 kcal: salad, nuts, fruit, etc.).
Study NCT05631990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209
Description: PO, Once daily(QD), 8weeks
Study NCT05631990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209-1A
Description: PO, Once daily(QD), 8weeks
Study NCT05631990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209-1B
Description: PO, Once daily(QD), 8weeks
Study NCT05631990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209-1C
Description: PO, Once daily(QD), 8weeks
Study NCT05631990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209 placebo
Description: PO, Once daily(QD), 8weeks
Study NCT05631990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209-1 placebo
Description: PO, Once daily(QD), 8weeks
Study NCT04921696 — intervention group
Intervention type: OTHER
Intervention: RBC transfusion
Description: RBC was transfused to the infants.
Study NCT04921696 — intervention group
Intervention type: OTHER
Intervention: no-RBC transfusion
Description: RBC was not transfused to the infants.
Study NCT05597683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)
Description: Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs,nefopam, and rescue opioids~Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs, nefopam, and rescue opioids
Study NCT05280470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: I-DXd will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (every Q3W).
Study NCT05556746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Daily therapy for 12 weeks
Study NCT05556746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Daily therapy for 12 weeks
Study NCT05556746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Daily therapy for 12 weeks
Study NCT05556746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Daily therapy for 12 weeks
Study NCT05556746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Daily therapy for 26 weeks
Study NCT05556746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Daily therapy for 26 weeks
Study NCT05556746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Daily therapy for 8 weeks
Study NCT05556746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Daily therapy for 8 weeks
Study NCT06236724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Given by PO
Study NCT06149702 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Combined intervention: Keep-on-Keep-Up-LITE (KOKU-LITE) programme and dementia and falls prevention leaflet
Description: KOKU-LITE programme will be used by the participants for 6 weeks and outcome assessments will be performed at baseline and 6 weeks of use. Participants will also use dementia and falls prevention leaflet for 6 weeks.
Study NCT06555731 — intervention group
Intervention type: GENETIC
Intervention: Ultra rapid genome sequencing
Description: DNA extraction from blood sample and whole genome sequencing
Study NCT04227288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar Foam
Description: Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
Study NCT05656027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine + Brimonidine
Description: LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
Study NCT05656027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine
Description: LNZ100 Aceclidine ophthalmic solution
Study NCT05656027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Description: Brimonidine ophthalmic solution
Study NCT05112302 — intervention group
Intervention type: OTHER
Intervention: Virtual reality
Description: Use of virtual reality goggles during procedure
Study NCT05125692 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: vaginal surgical repair of isthmocele
Description: after preoperative identification of the borders of the isthmocele using transvaginal ultrasound measurements, the isthmocele is repaired via vaginal approach
Study NCT06258837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DISE-Directed Surgery
Description: Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
Study NCT06258837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy
Description: Tonsil and/or adenoid removal
Study NCT04672538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Vt protocol
Description: Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2
Study NCT04672538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Vt protocol
Description: High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
Study NCT06653218 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: It is a observational study
Study NCT06653218 — intervention group
Intervention type: OTHER
Intervention: Not have interventions
Description: It is a observational study
Study NCT04832438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle